Clinical trials: Malignant Neoplasm of Prostate
Prostate Cancer, Metastatic Cancer
PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
Prostate cancer remains the most common malignancy in men in Europe. Over the last two decades, the treatment landscape for both localized and metastatic prostate cancer has been revolutionized.
- Conditions
- Prostate Cancer, Metastatic Cancer, Castrate Sensitive Prostate Cancer
- Trial name
- PSA-DEEP02 (NCT06652607)
- Testing
- Enzalutamide, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets
- Where
- Italy
- Volunteers
- 152 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer, Colorectal Cancer
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
RATIONALE: Printed educational materials, such as the Facing Forward Series: Life After Cancer Treatment manual, may help make the transition from cancer patient to cancer survivor easier in patients who are finishing treatment…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma
- Trial name
- NCT00372840
- Testing
- educational intervention, psychosocial assessment and care, quality-of-life assessment
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Fox Chase Cancer Center
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
This phase II trial tests the how well a precision medicine approach (serial measurements of molecular and architectural response to therapy [SMMART])-adaptive clinical treatment [ACT]) works in treating patients with sarcoma…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma
- Trial name
- NCT06630325
- Testing
- Abemaciclib, Biopsy, Bone Scan
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Neoplasm
COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer
In local advanced prostate cancer patients with clinically positive metastatic regional lymph node, the optimal treatment is still unanswered.
- Trial name
- NCT03241537
- Testing
- Intensity modulated radiotherapy
- Where
- South Korea
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
CLL, Solid Tumor, Adult
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
The goal of this clinical trial is to test the safety and preliminary efficacy of a new drug, KLS-1, in adults with different types of solid tumors and chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06506643
- Testing
- Zinc-64 Aspartate
- Where
- 2 sites in Ukraine
- Volunteers
- 36 people
- Sponsor
- Vector Vitale LLC
Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
This randomized phase IIA trial studies how well antiandrogen therapy works with or without axitinib before surgery in treating patients with previously untreated prostate cancer that is known or suspected to have spread to lymph…
- Conditions
- Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT01409200
- Testing
- Antiandrogen Therapy, Axitinib, Radical Prostatectomy
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Bone Metastases
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
A study to evaluate the safety and initial effectiveness of the ExAblate 2100 Conformal Bone System in the treatment of pain resulting from metastatic bone tumors.
- Trial name
- NCT00981578
- Testing
- ExAblate 2100
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- InSightec
Malignant Neoplasm of Prostate
Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease
The purpose of this study is to look at whether F-18 Fluciclovine (i.e. Axumin) is better or as good as F-18 Sodium Fluoride (F-18 NaF) when looking at bone disease from prostate cancer.
- Trial name
- NCT04765423
- Testing
- [F-18] NaF PET/CT, [F-18] fluciclovine PET/CT
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
This randomized pilot trial studies vaccine therapy and pembrolizumab in treating patients with prostate cancer that does not respond to treatment with hormones (hormone-resistant) and has spread to other places in the body…
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma
- Trial name
- NCT02499835
- Testing
- Pembrolizumab, pTVG-HP Plasmid DNA Vaccine
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer, Prostatic Neoplasm
68Ga PSMA in Preprostatectomy Patients
This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasm of Uncertain Behavior
- Trial name
- NCT03388346
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Michael Graham PhD, MD
Castrate Resistent Prostate Cancer
Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer
This is a Phase I, non-randomized, dose escalation study of the safety, biomarkers, and preliminary efficacy of dendritic cell vaccine, BPX-201, plus activating agent, AP1903, in patients with metastatic castrate resistant…
- Trial name
- NCT01823978
- Testing
- BPX-201 vaccine plus AP1903
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Bellicum Pharmaceuticals
Advanced Malignant Neoplasm, Advanced Melanoma
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
This trial studies the genetic analysis of blood and tissue samples from patients with cancer that has spread to other anatomic sites (advanced) or is no longer responding to treatment.
- Conditions
- Advanced Malignant Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03707574
- Testing
- Biospecimen Collection
- Where
- 144 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
MyProstateScore Equivalency With and Without DRE
The purpose of the study is to quantify the concordance of MPS results between first-catch urine samples collected post-DRE and those collected without a DRE.
- Trial name
- NCT05700370
- Testing
- MyProstateScore
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- LynxDx
Locally Advanced Malignant Neoplasm
Healthy Bones Study
Prostate cancer patients receiving hormone treatment (androgen deprivation therapy, or ADT) are at increased risk of developing bone loss and osteoporosis as side effects.
- Trial name
- NCT01973673
- Testing
- Bone health educational materials
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Prostatic Neoplasms, Prostate Cancer
Rectal Gas Removal Through Small Catheter Placement Prior to MRI of the Prostate
The presence of rectal gas can cause distortion at air-tissue interfaces on diffusion-weighted images (DWI) of prostate MRI and reduce image quality due to these susceptibility artifacts.
- Trial name
- GAS (NCT03987737)
- Testing
- small urinary catheter placement in the rectum
- Volunteers
- 46 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Spinal Tumor
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
The goal of the first part of this clinical research study is to learn how to deliver more accurate radiation treatment of tumors in the spine.
- Trial name
- NCT01624220
- Testing
- Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Breast Cancer
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
- Trial name
- NCT06533059
- Testing
- ALTA2618
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Alterome Therapeutics, Inc.
Urologic Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate
SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy
To evaluate the efficacy and safety of a pembrolizumab therapy of pembrolizumab in combination with standard salvage radiation therapy (SRT) in patients with biochemical recurrence (BCR) of prostate-specific antigen (PSA)…
- Trial name
- Pembro-SRT (NCT04931979)
- Testing
- Pembrolizumab Injection [Keytruda], Salvage Radiation Therapy (SRT)
- Where
- Germany
- Volunteers
- 49 people
- Sponsor
- Prof. Dr. med. Christian Gratzke
Malignant Neoplasm of Prostate
68Ga-AAZTA-093 PET/CT: First-in-human Study
68Ga-AAZTA-093 is a novel radiotracer targeting prostate-specific membrane antigen (PSMA). In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT in patients with…
- Trial name
- NCT06437496
- Testing
- 68Ga-AAZTA-093, 68Ga-PSMA-11//68Ga-PSMA-617
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University